Sundrug CoSDGCF 79 Return-on-Tangible-Equity is 10.36% as of Mar. 2026, which is 19% below its 10-year median of 12.82. GuruFocus rates SDGCF with a GF Score™ of 79/100 and a GF Value™ of $34.99. The stock has 1 warning sign investors should review. Among 582 Healthcare Providers & Services companies, Sundrug Co ranks better than 53.61% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sundrug Co's annualized net income for the quarter that ended in Mar. 2026 was $181 Mil. Sundrug Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $1,743 Mil. Therefore, Sundrug Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 10.36%.
The historical rank and industry rank for Sundrug Co's Return-on-Tangible-Equity or its related term are showing as below:
SDGCF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.51 Med: 12.82 Max: 17.93
Current: 11.71
During the past 13 years, Sundrug Co's highest Return-on-Tangible-Equity was 17.93%. The lowest was 11.51%. And the median was 12.82%.
SDGCF's Return-on-Tangible-Equity is ranked better than 53.61% of 582
companies
in the Healthcare Providers & Services industry
Industry Median: 10.065
vs SDGCF: 11.71
Sundrug Co (OTCPK:SDGCF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sundrug Co Return-on-Tangible-Equity Related Terms
Sundrug Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sundrug Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sundrug Co Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, Sundrug Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sundrug Co Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sundrug Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sundrug Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.36% mean?
Sundrug Co (SDGCF) has a Return-on-Tangible-Equity of 10.36% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sundrug Co and its competitors. This is 19% below median its historical median of 12.82. Over the past decade, Sundrug Co's Return-on-Tangible-Equity has ranged from 11.51 to 17.93. According to the industry distribution chart, Sundrug Co ranks #270 out of 582 companies in the Healthcare Providers & Services industry, placing it in the top 46.4%.
Is Sundrug Co's Return-on-Tangible-Equity too high?
Sundrug Co's current Return-on-Tangible-Equity of 10.36% is 19% below median its 10-year median of 12.82. Over the past 10 years, this metric has ranged from a low of 11.51 to a high of 17.93. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.07. Sundrug Co's value of 10.36% is 2.9% above this industry median. Based on the distribution chart, Sundrug Co ranks #270 out of 582 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Sundrug Co has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Sundrug Co's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sundrug Co ranks #270 out of 582 companies for Return-on-Tangible-Equity. This puts Sundrug Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.07. Sundrug Co's value of 10.36% is 2.9% above this benchmark. Historically, Sundrug Co's own Return-on-Tangible-Equity has ranged from 11.51 to 17.93 over the past decade. While the company's 10-year median is 12.82 vs. the industry median of 10.07, Sundrug Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.07, based on 582 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sundrug Co's current Return-on-Tangible-Equity of 10.36% is 2.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sundrug Co and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sundrug Co's current Return-on-Tangible-Equity is 10.36%, which is 19% below median its own 10-year median of 12.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sundrug Co stock overvalued right now?
Sundrug Co (SDGCF) has a current Return-on-Tangible-Equity of 10.36%. The stock's GF Value™ is $34.99, compared to a current price of $28.18 — trading 19.5% below its estimated fair value. The current Return-on-Tangible-Equity is 10.36%, which is 19% below median its 10-year median of 12.82 and 2.9% above the Healthcare Providers & Services industry median of 10.07. Sundrug Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sundrug Co (SDGCF), the current Return-on-Tangible-Equity is 10.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sundrug Co (SDGCF) Overvalued in 2026?
Based on GuruFocus' analysis, Sundrug Co stock appears to be undervalued.
The current stock price of $28.18 is trading 19.5% below its estimated GF Value™ of $34.99.
Key valuation signals for SDGCF:
Return-on-Tangible-Equity: 10.36% (19% below median its 10-year median of 12.82)
GF Value™: $34.99 vs. price of $28.18 (19.5% below fair value)
Industry Position: 2.9% above the Healthcare Providers & Services median (#270 of 582)
No single metric tells the full story. See the SDGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sundrug Co Ltd is a Japanese-based company engaged in the operation of drug stores and discount stores. The Group operates through two segments: the Drug Store Business, which mainly sells pharmaceuticals, cosmetics, and daily necessities, and the Discount Store Business, which mainly sells food products, household goods, and other related items. It generates the majority of its revenue from the Drugstore business segment.
79GF Score
Get the complete analysis for SDGCF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDGCF has been successfully added to your 
